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Abstract:  N,N’-bis(2-chloroethyl)-N-nitrosourea (BCNU) is one of the major drugs used in chemotherapy against
malignant gliomas due to its effects, such as induction of bifunctional alkylation of DNA and formation of interstrand
DNA cross-linkages, and induces cortical malformations in the fetal and neonatal rat brain.  In this study, pregnant rats
were treated with 7.5 mg/kg of BCNU on gestational day 13 (GD 13), and their fetuses were collected from 12 to 72
hours after BCNU treatment in order to examine the timecourses of morphological and immunohistochemical changes
in neural progenitor cells in the developing brain.  The number of pyknotic cells in the telencephalon peaked at 24 h
and then gradually decreased until 72 h.  The majority of these pyknotic cells were positive for cleaved caspase-3, a key
executioner of apoptosis.  The pyknotic cells showed the ultrastructural characteristics of apoptosis.  The number of p53-
positive cells began to increase prior to the appearance of apoptotic cells and p21-positive cells.  The number of
phosphorylated-histone H3-positive cells (mitotic cells) decreased from 24 to 36 h.  The number of Iba1-positive cells
(microglial cells) in the telencephalon increased from 12 to 48 h.  These results suggest that BCNU induces p53-
dependent apoptosis and reduces proliferative activity, resulting in reduction of the weight of the telencephalon and the
thickness of the telencephalic wall in the fetal brain.  This study will help to clarify the mechanisms of BCNU-induced
fetal brain toxicity.  (J Toxicol Pathol 2010; 23: 25–30)
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Introduction
N,N’-bis (2-chloroethyl)-N-nitrosourea (BCNU), also
called carmustine, is widely used in chemotherapy against
malignant gliomas1, 2 due to its effects, such as induction of
bifunctional alkylation of DNA and formation of interstrand
DNA cross-linkages3, 4.
In general, it is known that neural progenitor cells,
which are mainly located in the ventricular zone, proliferate
in the fetal developing brain.  Thereafter, the neural
progenitor cells differentiate into neural cells, i.e., neurons,
astrocytes and oligodendrocytes5.
It has also been also reported that BCNU induces
cortical malformations, such as reduced cortical size,
laminar disorganization and heterotopic clusters of neurons,
in the fetal and neonatal brain when pregnant rats are
exposed to BCNU6.  Since such BCNU-induced cortical
malformations in the rat brain show similar morphological
features to those of cortical dysplasia (CD) in humans with
epilepsy5, BCNU-induced cortical malformations in rats
have been used to study human CD7.  However, the
mechanisms of neural progenitor cell death in the fetal rat
brain after BCNU administration to dams are not fully
understood.
In order to clarify this, the present study was carried out
to examine the progression of neural progenitor cell death in
fetal rat brains obtained from BCNU-treated pregnant dams. 
Material and Methods
Animals
Thirty 13-week-old specific pathogen-free pregnant
rats of the Crl:CD(SD) strain were obtained from Charles
River Laboratories Japan Inc. (Kanagawa, Japan).  The
animals were individually housed in wire-mesh cages in an
air-conditioned animal room (temperature, 23 ± 3°C; relative
humidity, 50 ± 20%; ventilation, 12 to 17 /h; lighting, 12h/
12h-light/dark cycle) and were given a pelleted diet (CR-
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LPF, Oriental Yeast Co., Tokyo, Japan) and tap water ad
libitum.
Chemical
BCNU (Sigma-Aldrich Corporation, St. Louis, MO,
USA) dissolved in 5% glucose solution (Otsuka
Pharmaceutical Factory, Tokushima, Japan) was used.
Experimental design
On gestational day 13 (GD13), 15 pregnant rats were
injected i.p. with 7.5 mg/kg of BCNU, and 3 dams were
sacrificed by exsanguination from the abdominal aorta under
ether anesthesia at 12, 24, 36, 48 or 72 hours after BCNU-
treatment.  Fetuses were collected from each dam by
Caesarean section.  The remaining 15 pregnant rats were
injected i.p. with 5% glucose solution on GD13, sacrificed in
the same way and used as controls.  The protocol of the
present experiment was conducted according to the
Guidelines for Animal Experimentation outlined by the
Japanese Association for Laboratory Animal Science (1987).
Histopathology
The telencephalons of 3 randomly selected fetuses from
each dam, 9 fetuses of each time point, were resected and
weighed regardless of sex.  Due to the minimum size of the
telencephalon for histological preparation, the whole bodies
of other fetuses were fixed in 10% neutral-buffered formalin,
and 2 μm longitudinal paraffin sections were stained with
hematoxylin and eosin (HE).  For further histological
analysis, 3 fetal specimens in which we could recognize the
telencephalic vesicle were selected from each dam (9
telencephalons for each time point).
Immunohistochemistry
For immunohistochemical detection of cleaved
caspase-3 (Asp175), p53, p21, phosphorylated-histone H3
(Ser10) and Iba1, paraffin-embedded sections were
deparaffinized and immersed in 10 mM citrate buffer at pH
6.0 and heated at 121°C for 15 min by autoclaving.  After
being washed in Tris-buffered saline (TBS) containing 50
mM Tris-HCl (pH 7.6) and 150 mM NaCl, the sections were
placed in 3% H2O2-containing TBS for 5 min to inactivate
endogenous peroxidases.  The sections were then incubated
in 8% skimmed milk at 37°C for 30 min and reacted with
rabbit anti-cleaved caspase-3 antibody (dilution, 1:400; Cell
Signaling Technology, Beverly, MA, USA), rabbit anti-p53
polyclonal antibody (dilution, 1:300; Santa Cruz
Biotechnology, Santa Cruz, CA, USA), mouse anti-p21
monoclonal antibody (dilution, 1:25; Dako Cytomation,
Carpinteria, CA, USA), rabbit anti-phosphorylated-histone
H3 (Ser10) polyclonal antibody (dilution, 1:100; Cell
Signaling Technology) or rabbit anti-Iba1 polyclonal
antibody (dilution, 1:250; Wako, Osaka, Japan) at 4°C
overnight.  The sections were then reacted with
EnVision+system-peroxidase labeled polymer conjugated to
anti-rabbit IgG (DAKO) or to anti-mouse IgG (DAKO) at
37°C for 40 min.  Positive signals were visualized by the
peroxidase-diaminobenzidine (DAB) method.  The sections
were then counterstained with methyl green.
Electron microscopy
Small pieces of the telencephalon of one fetus were
fixed in 1.5% paraformaldehyde and 0.5% glutaraldehyde in
0.1 M phosphate buffer (pH 7.4), postfixed in 1% osmium
tetroxide and then embedded in epoxy resin (Oken Shoji,
Tokyo, Japan).  Ultrathin sections were stained with
toluidine blue for observation under a light microscope.
Ultrathin sections of the selected areas were double-stained
with uranyl acetate and lead citrate and observed under a
JEM-100CX II transmission electron microscope (Nippon
Denshi, Tokyo, Japan).
Morphometry
The thickness of the telencephalic wall recognized as
the thickest distance between the telencephalic vesicle and
surface was measured in HE-stained sections by micrometer
under a light microscope in the ventricular zone (VZ).
Pyknotic cells were counted in the same way on HE-stained
sections under a light microscope (× 400).  Three hundred
cells were counted in each fetus.  The cleaved caspase-3-,
p53-, p21-, phosphorylated-histone H3- and Iba1-positive
cells in the immunostained sections were counted in the
same way.  In addition, the microglial cell index (the number
of Iba1-positive cells/100 μm2) was represented as the mean
of 3 fetuses/dam × 3 dams.
Statistical analysis
The weight of the telencephalon, thickness of the
telencephalic wall and percentages of pyknotic cells and
cleaved caspase-3-, p53-, p21-, phosphorylated-histone H3-
and Iba1-positive cells in the BCNU-treated groups were
expressed as the mean ± standard deviation (SD) at each
point of examination.  Statistical analysis was carried out
using the Student’s t-test.
Results
In the fetal brains obtained from dams exposed to
BCNU on GD13, pyknosis of neural progenitor cells was
most prominent in the telencephalon (Fig. 1a), although it
was also observed in the diencephalon (Fig. 1b),
mesencephalon (Fig. 1c), metencephalon (Fig. 1d) and
spinal cord (Fig. 1e).  Therefore, we focused on the
telencephalon to investigate the progression of BCNU-
induced changes in the developing brain.  On the other hand,
pyknosis of neural progenitor cell was not observed in the
control groups.
The weight of the telencephalon and thickness of the
telencephalic wall in the BCNU-treated fetuses initially
showed significant reductions compared with those in the
control fetuses (Fig. 2).
In the telencephalon of the BCNU-treated fetuses, the
number of pyknotic neural progenitor cells peaked at 24 h
(Fig. 3Ab), gradually decreased toward 48 h and returned toYamaguchi, Kanemitsu, Yamamoto et al. 27
the control level by 72 h (Fig. 3B).  Pyknotic cells showed a
diffuse distribution within the VZ.  The number of cleaved
caspase-3-positive neural progenitor cells peaked at 24 h
(Fig. 4Ab) and returned to the control level by 72 h (Fig. 4B).
Ultrastructurally, the pyknotic cells were characterized by
shrinkage of the cell body and condensation and/or
marginalization of nuclear chromatin (Fig. 5).  The number
of p53-positive neural progenitor cells began to increase at
12 h, peaked at 24 h (Fig. 6Ab) and returned to the control
level by 72 h (Fig. 6B).  The number of p21-positive neural
progenitor cells began to increase at 24 h (Fig. 7Ab), and
returned to the control level at 48 h (Fig. 7B).  The number
of phosphorylated-histone H3 (Ser10)-positive neural
progenitor cells (mitotic cells) along the ventricular surface
began to decrease at 24 h (Fig. 8Ab), reached the lowest
level at 36 h and returned to the control level by 48 h (Fig.
8B).  The number of Iba1-positive cells (microglial cells)
peaked at 48 h (Fig. 9Ab) and returned to the control level by
72 h (Fig. 9B).
On the other hand, in the telencephalon of the control
fetuses, pyknotic, cleaved caspase-3, p53-, p21- and Iba1-
positive cells were not detected throughout the experimental
period (Figs. 3B, 4B, 6B, 7B and 9B).  The number of
phosphorylated-histone H3-positive mitotic cells was
significantly higher in the control fetuses than in the BCNU-
treated fetuses from 12 to 36 h (Fig. 8B).
Discussion
In the present study, neural progenitor cell death was
sequentially examined in the telencephalon of the fetal rat
brain following BCNU-administration to their dams on
GD13.
The majority of pyknotic cells observed in the present
study were positive for cleaved caspase-3.  Activated
caspase-3 is a key executioner of apoptosis, and activation of
caspase-3 in neural progenitor cells was observed during the
process of DNA-damaging agent-induced fetal brain
damage8, 9 as well as during normal fetal brain development.
In addition, the pyknotic cells showed the ultrastructural
characteristics of apoptotic cells10.  These findings indicate
that BCNU induces apoptotic cell death in neural progenitor
cells in the fetal rat brain.
In the present study, prior to the appearance of
apoptotic cells and p21-positive cells, the number of p53-
positive neural progenitor cells showed a significant increase
at 12 h.  p53 is a guardian of the genome, and it transactivates
p21 and other target genes, resulting in apoptotic cell death
and cell cycle arrest11.  Transactivated p21 is known to
inhibit cyclin dependent kinase activity, resulting in
depression of the proliferative activity of cells12, 13.  Judging
from these findings, it is reasonable to consider that BCNU-
induced neural progenitor cell apoptosis may be a p53-
related phenomenon.
Increased apoptosis of neural progenitor cells has also
been reported in fetal rat and mouse brains after treatment of
Fig. 1. Histology of the telencephalon (a), diencephalon (b),
mesencephalon (c), metencephalon (d) and spinal cord (e) of
BCNU-treated fetuses at 24 h. HE, Bar: 40 μm.
Fig. 2. A. Weight of the telencephalon of the fetal brain at 72 h.  B.
The telencephalon of a control fetus (a) and that of a BCNU-
treated fetus (b) at 72 h (HE).  C. Thickness of the
telencephalic wall at 72 h.  D. The telencephalic wall of a
control fetus (a) and that of a BCNU-treated fetus (b) at 72 h
(HE).  Each value represents the mean ± SD of 3 randomly
chosen fetuses per dam (× 3 dams).  **P<0.01. Bar: B, 1 mm;
D, 30 μm.28 Toxicity of BCNU in the Fetal Rat Brain
their dams with DNA damaging agents such as 5-
azacytidine14, 15, ethylnitrosourea16, etoposide17,
hydroxyurea18, 1-β-D-arabinofuranosylcytosine19 and 6-
mercaptopurine20.  Although the apoptosis of neural
progenitor cells in the fetal brain induced by these agents are
all considered to be p53-dependent, the peak time of
apoptosis differs among them.
It is well known that histone H3 protein is
phosphorylated during mitosis at two serine residues, Ser10
and Ser2821.  In the present BCNU-treated fetal rat brain, the
number of phosphorylated-histone H3 (Ser10)-positive cells
along the ventricular surface began to decrease at 24 h,
reached the lowest level at 36 h and recovered to the control
level by 48 h.  This suggests that BCNU induces depression
of proliferative activity in neural progenitor cells during
apoptosis.
In the present study, the weight of the telencephalon
and thickness of the telencephalic wall were significantly
decreased at 72 h in the BCNU-treated fetuses.  This was
thought to be a consequence of the above-mentioned BCNU-
induced apoptosis, depression of proliferative activity and
blockade of mitosis in neural progenitor cells.
Incidentally, Iba1 is widely used as a marker of
microglial cells22.  In the present study, no Iba1-positive
cells were detected in the telencephalic wall of the control
Fig. 3. A. Histology of the telencephalic wall of a control fetus (a)
and that of a BCNU-treated fetus (b) at 24 h. B.  Pyknotic  cell
index (%) in the fetal telencephalic wall. Each value represents
the mean ± SD of 3 randomly chosen fetuses per dam (× 3
dams) . **P<0.01. Arrows: pyknotic cells. HE, Bar: 40 μm.
Fig. 4. A. Immunostaining for cleaved caspase-3 in the
telencephalic wall of a control fetus (a) and that of a BCNU-
treated fetus (b) at 24 h.  B: Cleaved caspase-3-positive cell
index (%) in the fetal telencephalic wall.  **P<0.01. Arrows:
cleaved caspase-3-positive cells. Bar: 30 μm.
Fig. 5. Electron microscopy of a neural progenitor cell in the
telencephalic wall of a BCNU-treated fetus at 24 h.
Condensation of nuclear chromatin. Bar: 3 μm.Yamaguchi, Kanemitsu, Yamamoto et al. 29
fetal brain throughout the experimental period, while the
number of Iba1-positive cells increased from 12 to 48 h in
the telencephalic wall of the BCNU-treated fetal brains.
This suggests that microglial cells migrate into the
telencephalic wall to ingest and remove apoptotic neural
progenitor cells.
In conclusion, the present study clarified that BCNU
induces p53-dependent apoptotic cell death and depresses
cell proliferative activity in the fetal rat brain.  These effects
may cause development of BCNU-induced fetal and
neonatal cortical malformations5.  The present results will
help to clarify the mechanisms of BCNU-induced fetal brain
damage.  Further studies on gene expression levels are
necessary to elucidate the molecular pathway of BCNU-
induced fetal brain toxicity.
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Fig. 6. A. Immunostaining for p53 in the telencephalic wall of a
control fetus (a) and that of a BCNU-treated fetus (b) at 24 h.
B. p53-positive cell index (%) in the fetal telencephalic wall.
**P<0.01. Arrows: p53-positive cells. Bar: 40 μm.
Fig. 7. A. Immunostaining for p21 in the telencephalic wall of a
control fetus (a) and that of a BCNU-treated fetus (b) at 24 h.
B. p21-positive cell index (%) in the fetal telencephalic wall.
**P<0.01. Arrows: p21-positive cells. Bar: 40 μm.
Fig. 8. A. Immunostaining for phosphorylated-histone H3 (Ser10) in
the ventricular surface of the telencephalic wall of a control
fetus (a) and that of a BCNU-treated fetus (b) at 24 h.  B.
Phosphorylated-histone H3 (Ser10)-positive cell (mitotic cell)
index in the fetal telencephalic wall.  **P<0.01. Arrowheads:
phosphorylated-histone H3 (Ser10)-positive cells.  HE, Bar:
20 μm.30 Toxicity of BCNU in the Fetal Rat Brain
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Fig. 9. A. Immunostaining for Iba1 in the telencephalic wall of a
control fetus (a) and that of a BCNU-treated fetus (b) at 48 h.
B. Iba1-positive cell index (%) in the telencephalon.
**P<0.01. Arrows: Iba1-positive cells. Bar: 40 μm.